METHYLOMIC DNA methylation markers to predict treatment success of biologicals in Crohn’s disease.
- Coordinator
- Stichting Amsterdam Umc, Netherlands
- Runs
- 1 January 2023 to 31 December 2026
- Status
- Running
- EU funding
- €9.4m
- Total cost
- €9.4m
- Partners
- 18 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101095449
What the project is doing
In the project's own words, from its summary on CORDIS.
Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO). Current therapeutics include antibodies (“biologicals”) targeting inflammatory proteins such as Tumor Necrosis Factor (adalimumab), leukocyte trafficking (vedolizumab), or IL-12/IL-23 (ustekinumab). At present however, it cannot be predicted which biological will be effective in an individual patient, with only <40% of patients showing primary response to any given therapeutic.
Treatment failure is associated with disease complications, and increased health care costs.. Hence the overwhelming need for predictive biomarkers to guide personalised medicine in IMID is evident. No biomarker to target therapy is validated in clinical practice. In METHYLOMIC, we build on multiple previous cohort studies in which we confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD.
Specifically, we discovered and validated differential DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for 3 approved biologicals in CD. Through the use of machine learning algorithms, treatment response could be predicted with up to 93% accuracy for each biological for CD, and RA. METHYLOMICS is committed to bringing personalised treatment-selection in CD and other IMID to clinical practice.
We have teamed up clinical, epigenetic, and DNA diagnostics experts, patient organisations, and companies across Europe, for further validation studies, develop a marketable rapid targeted methylation assay that we than validate in a unique prospective randomised clinical trial for CD. Efficiency and cost-effectiveness is assessed in great detail and regulatory approval is guided by experts to assure delivery of the first epigenetic kit personalised treatment of CD.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Coordinator |
| Belgian Ibd Research and Development | Zaventem | Belgium | Participant |
| Diagenode | Seraing | Belgium | Associatedpartner |
| International Federation of Crohn's and Ulcerative Colitis Associations | Bruxelles / Brussel | Belgium | Participant |
| Universiteit Gent | Gent | Belgium | Participant |
| Asphalion SL | Barcelona | Spain | Participant |
| Szegedi Tudomanyegyetem | Szeged | Hungary | Participant |
| Universita Vita-Salute San Raffaele | Milano | Italy | Participant |
| Alimentiv BV | Amsterdam | Netherlands | Participant |
| Descin BV | Vinkeveen | Netherlands | Participant |
| Genome Diagnostics B.v | Utrecht | Netherlands | Participant |
| Horaizon Technology B.v. | Delfgauw | Netherlands | Participant |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| Univerzitetni Klinicni Center Ljubljana | Ljubljana | Slovenia | Participant |
| King's College London | London | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
| Twist Bioscience Coorporation | South San Francisco | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI